Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis® CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza® (olaparib). BRACAnalysis CDx is the only germline test covered for this indication.
“One in six patients with prostate cancer have a hereditary form of the disease and are six times more likely to die from it within five years,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Providers with earlier knowledge of their patient’s germline status can help tailor treatments and can provide eligibility for life-sustaining therapies should they progress to metastasis. Additionally, the information can be provided to the patient’s family members to prevent future cancers.”
According to the American Cancer Society, 191,930 new cases of prostate cancer occur every year and approximately 33,330 men will die from the disease this year. In May, the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis® CDx test for use as a companion diagnostic tool by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza® (olaparib). Lynparza, a non-chemotherapy oral medication, is approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
About BRACAnalysis® CDx
About Myriad Genetics
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
IoT Security Against Global Cybercrime
Key Tools of the IoT Security Trade